ZALTRAP (ziv-aflibercept)
ZALTRAP is indicated for the treatment of Colorectal Cancer.
How ZALTRAP Works
Ziv-aflibercept functions as a soluble receptor that binds to human VEGF-A, VEGF-B, and placental growth factor (PlGF). By binding to these endogenous ligands, the drug prevents them from interacting with and activating their cognate receptors. This inhibition results in decreased neovascularization and vascular permeability, which hinders the proliferation of endothelial cells and the growth of new blood vessels.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2012-08-03
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
ZALTRAP Approval History
What ZALTRAP Treats
1 indicationsZALTRAP is approved for 1 conditions since its original approval in 2012. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Colorectal Cancer
ZALTRAP Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
ZALTRAP Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in ZALTRAP's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications ZALTRAP treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to ZALTRAP
3 of 8FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
15 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02298959 | NCI-2014-01984 NCI-2014-01984, 15-703 | Ph 1 | active not recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer |
| NCT06121180 | MCC-21341 R2810-ONC-2128 | Ph 2 | recruiting | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma |
| NCT02159989 results posted | NCI-2014-01107 NCI-2014-01107, 2013-0665 | Ph 1 | completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
| NCT03712904 results posted | 18P.457 JT 11801 | Ph 2 | terminated | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma |
| NCT01782443 results posted | 12-456 | Ph 2 | completed | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors |
| NCT02101918 results posted | NCI-2014-00642 NCI-2014-00642, 2013-0954 | Ph 2 | completed | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery |
| NCT01747551 results posted | 12-401 | Ph 2 | completed | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer |
| NCT01258855 results posted | NCI-2011-02498 NCI-2011-02498, PHII-107 | Ph 2 | completed | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery |
| NCT02192541 results posted | 140150 14-C-0150 | Ph 1 | terminated | Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas |
| NCT00828139 results posted | NCI-2009-01182 NCI-2009-01182, SWOG-S0802 | Ph 2 | completed | S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
| NCT00729157 results posted | NCI-2009-00178 NCI-2009-00178, MSKCC-08066 | Ph 2 | completed | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy |
| NCT02235324 | 3C-13-7 NCI-2014-01806, HS-14-00081 | Ph 2 | withdrawn | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer |
| NCT01889680 | NSABP FC-8 | Ph 2 | withdrawn | Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer |
| NCT00650923 | NCI-2009-00678 NCI-2009-00678, CDR0000590174 | Ph 1 | completed | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma |
| NCT00622414 | NCI-2009-01062 NCI-2009-01062, COG-ADVL0714 | Ph 1 | completed | Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ZALTRAP FDA Label Details
Indications & Usage
FDA Label (PDF)ZALTRAP is indicated for the treatment of Colorectal Cancer.
Track ZALTRAP with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment